Evidence map›Paper›PMID 33797782›Full record

ArticleJournal of neurochemistry2021

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease.

Filipe B Rodrigues, Lauren M Byrne, Alexander J Lowe, Rosanna Tortelli, Mariette Heins, Gunnar Flik, Eileanoir B Johnson, Enrico De Vita, Rachael I Scahill, Flaviano Giorgini and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Filipe B RodriguesUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0002-5567-7938
Lauren M ByrneUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Alexander J LoweUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Rosanna TortelliUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Mariette HeinsCharles River Laboratories, Groningen, The Netherlands.
Gunnar FlikCharles River Laboratories, Groningen, The Netherlands.
Eileanoir B JohnsonUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Enrico De VitaLysholm Department of Neuroradiology, National Hospital for Neurology & Neurosurgery, London, UK.
Rachael I ScahillUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Flaviano GiorginiDepartment of Genetics and Genome Biology, University of Leicester, Leicester, UK.
Edward J WildUCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Huntington's Disease Association · GBCharles River Laboratories (Netherlands) · NLKing's College London · GBUniversity of Leicester · GB

Funding

Medical Research Council MR/M008592/1Medical Research Council MR/N00373X/1
6 · The paper itself

Abstract

Converging lines of evidence from several models, and post-mortem human brain tissue studies, support the involvement of the kynurenine pathway (KP) in Huntington's disease (HD) pathogenesis. Quantifying KP metabolites in HD biofluids is desirable, both to study pathobiology and as a potential source of biomarkers to quantify pathway dysfunction and evaluate the biochemical impact of therapeutic interventions targeting its components. In a prospective single-site controlled cohort study with standardised collection of cerebrospinal fluid (CSF), blood, phenotypic and imaging data, we used high-performance liquid-chromatography to measure the levels of KP metabolites-tryptophan, kynurenine, kynurenic acid, 3-hydroxykynurenine, anthranilic acid and quinolinic acid-in CSF and plasma of 80 participants (20 healthy controls, 20 premanifest HD and 40 manifest HD). We investigated short-term stability, intergroup differences, associations with clinical and imaging measures and derived sample-size calculation for future studies. Overall, KP metabolites in CSF and plasma were stable over 6 weeks, displayed no significant group differences and were not associated with clinical or imaging measures. We conclude that the studied metabolites are readily and reliably quantifiable in both biofluids in controls and HD gene expansion carriers. However, we found little evidence to support a substantial derangement of the KP in HD, at least to the extent that it is reflected by the levels of the metabolites in patient-derived biofluids.

Indexed as

Signal TransductionAdultAgedBiomarkersChromatography, High Pressure LiquidCohort StudiesFemaleHumansHuntington DiseaseKynurenineMagnetic Resonance ImagingMaleMiddle AgedPhenotypeProspective StudiesBiomarkersKynureninebiomarkersbloodcerebrospinal fluidcohort studiesHuntington's diseaseKynurenine

Identifiers

PMID33797782
PMCPMC8375100
OpenAlexW3146010890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.